Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients (Q35807156)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 June 2015

Language	Label	Description	Also known as
English	Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients	scientific article published on 19 June 2015

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients (English)

1 reference

Europe PubMed Central

10 August 2017

author name string

Ramesh Saeedi

1

1 reference

Europe PubMed Central

10 August 2017

Kevin Johns

2

1 reference

Europe PubMed Central

10 August 2017

Jiri Frohlich

3

1 reference

Europe PubMed Central

10 August 2017

Matthew T Bennett

4

1 reference

Europe PubMed Central

10 August 2017

Gregory Bondy

5

1 reference

Europe PubMed Central

10 August 2017

publication date

19 June 2015

1 reference

Europe PubMed Central

10 August 2017

Lipids in Health and Disease

1 reference

Europe PubMed Central

10 August 2017

14

1 reference

Europe PubMed Central

10 August 2017

57

1 reference

Europe PubMed Central

10 August 2017

copyright license

Creative Commons Attribution 4.0 International

19 June 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s12944-015-0054-x

0 references

Serum lipids, apolipoproteins, and mortality among coronary artery disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Genetically elevated C-reactive protein and ischemic vascular disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Are HIV positive patients resistant to statin therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

11 July 2018

Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

The concept of precision extended to the atherogenic index of plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4488121

25 September 2018

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

1 reference

https://api.crossref.org/works/10.1186%2FS12944-015-0054-X

21 January 2018

Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1186%2FS12944-015-0054-X

21 January 2018

Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals

1 reference

https://api.crossref.org/works/10.1186%2FS12944-015-0054-X

21 January 2018

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

1 reference

https://api.crossref.org/works/10.1186%2FS12944-015-0054-X

21 January 2018

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/26087958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26087958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26087958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins

1 reference

https://pubmed.ncbi.nlm.nih.gov/26087958

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12944-015-0054-X

1 reference

Europe PubMed Central

10 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35807156&oldid=1856472940"